Enterprise controls a network of pipelines, for both oil and natural gas, totaling over 50,000 miles, along with storage facilities adequate for 160 million barrels of oil and 14 billion cubic feet of gas, and shipping terminals located in the hydrocarbon-rich Gulf coast of Texas.Even with revenues and earnings slipping in the first half of this year, Enterprise finished 1H20 with solid liquidity. Proof-of-concept data for lead program NTLA-2001, its therapy targeting transthyretin amyloidosis (ATTR), a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues, could come by mid-2021.
Q2 saw a reversal, as the effects of the pandemic hit Enbridge. This figure implies a strong 47% one-year upside from current levels.
The CEO took the stage at the company's shareholder meeting, in which key company proposals were approved, and ahead of the battery event. (To watch Sighinolfi’s track record, click here)Overall, Enterprise gets a Strong Buy rating from the analyst consensus, and it is unanimous, based on 7 recent Buy reviews.
Analysts expected Take-Two earnings of $1.60 a share on sales of $843.7 million. That goes hand-in-hand with a perception that COVID-19 is beginning to face back, and there are signs that another lockdown may be coming. (To watch Richter’s track record, click here)Looking at the consensus breakdown, 3 Buys and 2 Holds have been published in the last three months.
VIR recently initiated the Phase 2/3 COMET-ICE study of VIR-7831, its mAb for COVID-19, as a monotherapy (versus a combination approach) in patients with mild or moderate COVID-19. This data stands to “inform the drug’s clinical profile (safety/tolerability and early signs of sustained TTR knockdown),” which would de-risk NTLA’s in vivo editing platform, in Richter’s opinion.On top of this, IND-enabling studies for NTLA-2002, its therapy designed for hereditary angioedema (HAE), and NTLA-5001, its therapy for WT1+ acute myeloid leukemia (AML), are set to kick off in 2021. (To watch Terry’s track record, click here)In general, other analysts are on the same page. Bill Gates-backed electric vehicle battery startup comes into limelight,Trump says aides rejected his request to adjust value of dollar,Estate Planning: 16 Things to Do Before You Die,Americans are hoarding trillions of dollars in cash before the presidential election: Morgan Stanley,Exclusive: Wells Fargo CEO ruffles feathers with comments about diverse talent,zeroUV - Retro Round Sunglasses for Men Women with,These cheap stocks could see huge gains during a vaccine-driven economic rebound,Peloton Slips After Echelon Reveals $499 'Prime Bike' With Amazon,Goldman Sachs: These 3 Stocks Are Poised to Surge by at Least 50%.Aurora Cannabis Lost Ground in the Canadian Pot Market.
Take Two Interactive's (TTWO) Q1 results are expected to reflect portfolio strength and solid increase in recurrent consumer spending supported by … That being said, Terry’s bullish thesis remains very much intact.Expounding on this, the analyst said, “... we believe that the window of opportunity for any meaningful competitor is rapidly closing, something that, along with the large and expanding addressable market for Peloton’s high ARPU, high margin, extremely low churn subscription business, remains underappreciated by the market, even with the stock’s recent outperformance.”It should come as no surprise, then, that Terry stayed with the bulls. The company’s portfolio generated over $1.5 billion in revenue last year.
The payment, at 44.5 cents, has been increased gradually over the past 12 years. In 2018, Coca-Cola also launched Lemon-Do - and alcoholic drink in Japan.In 2017, Coco-Cola acquired the Mexican company Topo Chico for $220 million.Why Does It Matter: CNBC cited research by Bump Williams Consulting Co., which estimated a Hard Seltzer sales figure of $3 billion in the U.S for the 12 months ended in mid-July.Constellation Brands Inc (NYSE: STZ), which produces Corona beer, also ventured in the fast-growing Hard Seltzer market this year.
Authors may own the stocks they discuss.
)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.Restaurant bankruptcies are starting to pile up.With no prior experience, Kyle Dennis decided to invest in stocks. Proof-of-concept data for lead program NTLA-2001, its therapy targeting transthyretin amyloidosis (ATTR), a slowly progressive condition characterized by the buildup of abnormal deposits of a protein called amyloid (amyloidosis) in the body's organs and tissues, could come by mid-2021. The content is intended to be used for informational purposes only. Richter estimates that peak sales for both candidates could reach $895 million and $806 million, respectively, with data from both also validating “the breadth of editing approaches (knockouts and/or insertions).”If that wasn’t enough, Richter cites the ongoing NVS-led Phase 1/2 OTQ923 sickle cell disease (SCD) trial as a possible upside driver.
Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.Take-Two appears a compelling earnings-beat candidate. Or will we see a state-by-state reaction.
(To watch Richter’s track record, click here)Looking at the consensus breakdown, 3 Buys and 2 Holds have been published in the last three months. Should the 5-star analyst’s thesis play out, a twelve-month gain of 69% could potentially be in the cards. Adjusted EBITDA came in at $143.6 million, ahead of the Street’s $73.5 million call. Volatility has ruled the Street for the last few weeks, leading some to conclude that those with a more pessimistic outlook had been vindicated, but the firm believes stocks can still climb higher.According to Goldman Sachs’ head of U.S. equity strategy, David Kostin, the S&P 500 could still hit 3,600 by the end of the year, and 3,800 by mid-2021, on the back of vaccine-related optimism and progress with the economic reopening.